publi\u00e9s le 4\u00a0ao\u00fbt dans une revue m\u00e9dicale de r\u00e9f\u00e9rence, The Lancet<\/a>, men\u00e9 chez des femmes \u00e2g\u00e9es atteintes de cancers du sein hormonod\u00e9pendants \u2013 les plus fr\u00e9quentes des tumeurs du sein, soit 70\u00a0%\u00a0d\u2019entre\u00a0elles,\u00a0tout particuli\u00e8rement \u00e0 partir de 70 ans.<\/p>\n\u00ab\u00a0Cela a-t-il du sens de s\u2019acharner \u00e0 faire de la chimioth\u00e9rapie chez toutes les patientes de plus de 70\u00a0ans op\u00e9r\u00e9es d\u2019un cancer du sein hormonod\u00e9pendant, en plus de leur hormonoth\u00e9rapie\u00a0?\u00a0\u00bb C\u2019est la question que pose le professeur Etienne Brain, oncologue \u00e0 l\u2019Institut Curie \u00e0 Saint-Cloud (Hauts-de-Seine), \u00e0 la lumi\u00e8re des r\u00e9sultats de cette \u00e9tude qu\u2019il a coordonn\u00e9e.<\/p>\n
Promu par le r\u00e9seau Unicancer et men\u00e9 dans 84\u00a0centres cliniques en France et en Belgique, cet essai, nomm\u00e9 \u00ab\u00a0Aster 70s\u00a0\u00bb, a recrut\u00e9 1\u00a0969\u00a0patientes atteintes d\u2019un tel cancer, \u00e2g\u00e9es de 70 \u00e0 95\u00a0ans (\u00e2ge m\u00e9dian de 75,1\u00a0ans), entre avril\u00a02012 et avril\u00a02016. Toutes avaient \u00e9t\u00e9 op\u00e9r\u00e9es de leur tumeur. Pour chacune d\u2019elles, le tissu tumoral a \u00e9t\u00e9 pass\u00e9 au crible d\u2019un biomarqueur pronostique, le \u00ab\u00a0grade g\u00e9nomique\u00a0\u00bb. D\u00e9velopp\u00e9 par Ipsogen, ce test analyse quatre g\u00e8nes impliqu\u00e9s dans la prolif\u00e9ration des cellules tumorales\u00a0; cette signature g\u00e9nomique livre alors un indice de l\u2019agressivit\u00e9 du cancer.<\/p>\n
Il vous reste 80.67% de cet article \u00e0 lire. La suite est r\u00e9serv\u00e9e aux abonn\u00e9s.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"Mammographie lors d\u2019un examen de d\u00e9pistage du cancer du sein \u00e0 Woerden, Pays-Bas, le 29\u00a0novembre 2023. ROBIN VAN…\n","protected":false},"author":2,"featured_media":362152,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[1011,27,72,71],"class_list":{"0":"post-362151","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-fr","9":"tag-france","10":"tag-health","11":"tag-sante"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115137848841501435","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/362151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=362151"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/362151\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/362152"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=362151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=362151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=362151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Mammographie](\"https:\/\/www.europesays.com\/fr\/wp-content\/uploads\/2025\/09\/10ddb6b_upload-1-qvktvo4hjey2-043-485029301.jpg\")
Mammographie lors d\u2019un examen de d\u00e9pistage du cancer du sein \u00e0 Woerden, Pays-Bas, le 29\u00a0novembre 2023. ROBIN VAN LONKHUIJSEN \/ ANP VIA AFP <\/p>\n